Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Launched by SHENZHEN YANGLI PHARMACEUTICAL TECHNOLOGY CO., LTD · Feb 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new experimental treatment called VB15010, which is designed to help patients with advanced solid tumors, including various types of cancer like breast, ovarian, pancreatic, and colorectal cancer. The main goal of the study is to find out if this treatment is safe to use, if patients can tolerate it, and whether it has any effects on reducing cancer.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of advanced cancer that is worsening. You should also have a specific genetic mutation related to cancer repair processes. However, if you've had major surgery recently, or have certain severe complications like untreated brain issues, you may not be eligible. Participants will receive the treatment and will be monitored closely to evaluate its effects and safety. This study is currently recruiting patients, so if you or someone you know is interested, it could be a potential option for exploring new cancer therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 at the time of screening;
• • Histological or cytological confirmation of advanced malignancy ;
• • Progressive cancer at the time of study entry;
• • Adequate organ and marrow function as defined by the protocol;
• • Homologous recombination repair gene mutation.
• Exclusion Criteria:
• • Major surgery within 4 weeks of the first dose of study treatment.
• • Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \>10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.
• • Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).